Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-67

As an addendum to the above, I like to think that even if formalised DMOAD status proved elusive, and the agencies too non-commital on an achievable strategy.....all is not lost.

I, personal views only, think that a Zilosul approved as a pain/function therapeutic only will quickly gain an informal reputation amongst physicians and patients as a disease-modifying drug and will benefit from sales accordingly, in turn this will afford a lengthy runway for price increases over time.

We know what this drug does, and can do. Once it's on the market it will sell at profound scale.